

Meeting with [REDACTED], [REDACTED] at TransAtlantic Consumer Dialogue (TACD) on 18 February 2015

[REDACTED] and [REDACTED] participated.

[REDACTED] had requested the meeting to discuss "access to medicines issues in Europe today and the EC priorities regarding healthcare industry for 2015".

[REDACTED] clarified that the proposal of revision of the transparency directive was withdrawn, although the parliament had not had its say yet. Enforcement of the TD was now on the agenda. The Transparency Committee would be an arena for further discussions for MS and COM. For transparency in relations (among other things) there was the multistakeholder meeting.

Mentioning the council conclusions on innovation for the benefit of patients, [REDACTED] expressed that TACD viewed the formulations on information sharing and transparency of prices as encouraging.

[REDACTED] explained the different competences of SANTE and GROW.

[REDACTED] raised the issue of differential pricing and commented that it was a subject worth exploring and that they had no objection to the concept.

[REDACTED] also inquired whether the time was right to address more fundamental issues such as raising issues of alternatives to the current model of financing medical R&D. [REDACTED] suggested to wait for institutional things to settle and then the timing for raising such issues might be better.

On the issue of TTIP, [REDACTED] ensured that COM has no intention to cover pricing and reimbursement in any FTA.